Cargando…
Intra- and Inter-Tumor Heterogeneity of BRAF(V600E)Mutations in Primary and Metastatic Melanoma
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends, at least in part, on the assumption that metastatic tumors are primarily clonal with respect to mutant oncogene. With the emergence of BRAF(V600E) as a therapeutic target, we investigated intra- and...
Autores principales: | Yancovitz, Molly, Litterman, Adam, Yoon, Joanne, Ng, Elise, Shapiro, Richard L., Berman, Russell S., Pavlick, Anna C., Darvishian, Farbod, Christos, Paul, Mazumdar, Madhu, Osman, Iman, Polsky, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250426/ https://www.ncbi.nlm.nih.gov/pubmed/22235286 http://dx.doi.org/10.1371/journal.pone.0029336 |
Ejemplares similares
-
Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis
por: Weiss, Sarah, et al.
Publicado: (2015) -
Clinical relevance of Neutral Endopeptidase (NEP/CD10) in melanoma
por: Velazquez, Elsa F, et al.
Publicado: (2007) -
BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016) -
Deletion of PTENP1 pseudogene in human melanoma
por: Poliseno, Laura, et al.
Publicado: (2011) -
Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients
por: Yu, Jessie Z, et al.
Publicado: (2008)